Introduction

Every child is different. This is not simply a comforting thought for parents. It is a fundamental biological truth that modern medicine is only now beginning to act upon in a meaningful and systematic way. For generations, pediatric care operated on a framework largely borrowed from adult medicine, scaled down by weight and age, but rarely accounting for the unique genetic blueprint each child carries. That approach is now being redefined.

Personalized medicine, also referred to as precision medicine, is a healthcare model in which treatment decisions are shaped by an individual's genetic makeup, biological markers, developmental stage, lifestyle, and environmental exposures. For children, this shift holds extraordinary promise. Childhood is a period of rapid growth, hormonal change, immune development, and neurological maturation. These factors interact with disease in ways that differ profoundly from how adults experience illness. A therapy that works well in an adult may be ineffective or even harmful in a child of six or ten years of age.

Across India, where millions of children still face preventable diseases, underdiagnosis of rare genetic conditions, and wide variation in healthcare access, personalized medicine represents not just a scientific advancement but a genuine opportunity to reimagine child health from the ground up. Medicircle explores this emerging frontier, with an eye toward what it means for Indian families, pediatricians, and the future of child healthcare in the country.

Understanding Personalized Medicine in the Context of Child Health

At its core, personalized medicine in pediatrics moves away from the traditional model of "one drug, one dose, one disease" and toward a far more sophisticated understanding of how a child's body works. The foundational principle is that genetic variation affects how individuals respond to diseases, medications, and environmental stressors. When this knowledge is applied to children specifically, the clinical possibilities expand dramatically.

Precision pediatric care draws from several interconnected disciplines:

• Genomics: The study of a child's entire genetic code to identify disease risk, diagnose rare conditions, and guide treatment decisions.
• Pharmacogenomics: The science of understanding how genetic variants influence a child's response to specific drugs, including metabolism speed, efficacy, and risk of adverse effects.
• Multi-omics integration: The combined analysis of genomics, transcriptomics, proteomics, and metabolomics to build a complete biological picture of a child's health status.
• Biomarker-driven therapy: Using specific biological markers in blood or tissue to predict disease progression and personalize treatment intensity.

What makes this especially relevant to children is that the physiological pathways governing how the body processes drugs continue to develop well into adolescence. As researchers have noted in peer-reviewed literature, the pathways affecting drug distribution and response change as children grow and develop, which means that medication choices must account for both genetic variation and developmental stage simultaneously.

Why Children Are Not Simply Small Adults: The Clinical Gap

One of the most persistent problems in pediatric medicine has been the historic underrepresentation of children in clinical drug trials. Most medications used in pediatric settings were originally tested and approved for adult populations. Dosages for children have long been calculated as rough proportional estimates rather than evidence-based, age-specific formulations. This is a gap that has real consequences.

Adverse drug reactions in children are a significant and often underreported clinical problem. Genetic variations in drug-metabolizing enzymes can cause a child to process a medication too rapidly, making it ineffective, or too slowly, causing toxicity. Without pharmacogenomic testing, prescribing doctors are essentially working with incomplete information.

This challenge is particularly sharp in India. A 2024 analysis published in an international peer-reviewed journal noted that India's pediatric essential medicines list requires revisiting, and that access to pediatric-specific formulations remains uneven across states. In urban tertiary hospitals in cities like Mumbai, Bengaluru, and Delhi, there is growing adoption of genomic diagnostics. However, in Tier 2 and Tier 3 cities, access to even basic genetic testing remains limited.

At the same time, India carries a significant burden of rare genetic diseases in children, many of which are inherited in a recessive pattern due to high rates of consanguineous marriage in certain communities. Conditions such as spinal muscular atrophy, thalassemia, inborn errors of metabolism, and rare lysosomal storage disorders affect thousands of Indian children annually. Without genomic tools, many of these children experience what researchers call the "diagnostic odyssey," years of misdiagnosis, unnecessary investigations, and delayed treatment.

Pharmacogenomics: Getting the Right Drug to the Right Child

Of all the pillars of personalized pediatric medicine, pharmacogenomics is perhaps the most immediately actionable. It does not require the development of new drugs. It simply requires matching the right existing drug to a child's genetic profile.

Research published in leading scientific journals has demonstrated that genetic variants in drug-metabolizing enzymes can significantly influence whether a medication is effective, ineffective, or dangerous for a specific child. For children with childhood asthma, which affects a large proportion of Indian children in urban areas due to air pollution exposure, pharmacogenomic profiling can help identify which subgroup will respond to beta-2 agonists, corticosteroids, or leukotriene antagonists. This avoids the cycle of trial and error that many families go through before finding a medication that works.

For childhood cancers, the role of pharmacogenomics is even more critical. Pediatric oncology has seen some of the most remarkable advances in personalized therapy in recent years. Genetic profiling of tumors in children with leukemia, brain tumors, and solid malignancies is now guiding treatment selection in leading centers globally. In India, institutions such as Tata Memorial Hospital in Mumbai and the Pediatric Oncology units at AIIMS New Delhi are gradually integrating molecular tumor profiling into their treatment workflows.

A landmark development in 2025 was the successful use of a personalized CRISPR-based gene editing therapy in an infant born with a rare urea cycle disorder. This bespoke therapy, designed specifically around the child's unique genetic mutation, reduced dependence on medications and improved the child's ability to tolerate protein in the diet. While such cutting-edge interventions remain distant for most Indian hospitals, they signal the direction in which pediatric medicine is moving.

Rare Diseases, Genomic Diagnosis, and the Indian Scenario

India is estimated to have approximately 70 to 80 million people living with rare diseases, a significant proportion of whom are children. Many of these conditions have a genetic basis, and the path from first symptom to confirmed diagnosis can stretch for years. Studies globally have shown that whole-exome sequencing, when applied to carefully selected pediatric populations with unexplained symptoms, can achieve diagnostic yields of 40 to 50 percent, transforming outcomes for children who would otherwise remain undiagnosed.

The Indian government has taken initial steps in this direction. The National Policy for Rare Diseases, notified in 2021 and updated subsequently, recognizes the need for genomic testing support and treatment funding for children with rare genetic conditions. Initiatives under the Ayushman Bharat scheme are being examined for potential coverage of rare disease therapies, though implementation remains a work in progress.

Several specialized centres across India, including those supported by the Department of Biotechnology, ICMR, and select private hospital networks, are conducting genomic sequencing research in pediatric populations. The challenge remains bridging the gap between research discoveries made in tertiary institutions and the clinical care available to children in smaller towns and rural areas.

Artificial intelligence is also beginning to play a role in rare disease diagnosis for children. AI-powered tools trained on large clinical and genomic datasets can detect patterns that human clinicians may miss, particularly in conditions with highly variable presentations. For pediatricians in resource-limited settings, such tools hold the potential to flag children who need genomic workup early, reducing the length and cost of the diagnostic journey.

Precision Nutrition and Environmental Personalisation in Child Health

Personalized medicine for children is not limited to genomics and drug therapy. It extends into the domain of nutrition, a critical area in Indian pediatric health. Childhood malnutrition in India remains a public health concern, and emerging research suggests that nutritional interventions may need to be tailored based on a child's genetic predisposition to absorb and metabolize specific micronutrients.

For instance, variants in genes that govern folate metabolism, iron absorption, vitamin D processing, and lactase production can affect how a child responds to standard supplementation protocols. A child who does not respond to iron therapy may have a genetic variant that impairs absorption rather than simply insufficient dietary intake. Recognizing this distinction can change clinical management meaningfully.

Similarly, environmental exposures, including air quality, water quality, and early childhood infections, interact with genetic predispositions to shape long-term health trajectories. Precision child health frameworks account for this gene-environment interaction as a core principle of personalised care.

Challenges in Bringing Personalized Pediatric Care to India

The promise of personalized medicine for children is significant. However, a clear-eyed assessment of where India currently stands is equally important. Several barriers must be acknowledged:

• Cost: Whole-genome sequencing and pharmacogenomic panels remain expensive, often ranging from tens of thousands to several lakh rupees, placing them beyond reach for the majority of Indian families.
• Specialist shortage: The number of trained clinical geneticists and pediatric precision medicine specialists in India is far below what is needed for widespread adoption.
• Data gaps: Most global genomic databases used in clinical decision-making are built predominantly on data from European and American populations. Indian-specific pediatric genomic datasets are limited, which affects diagnostic accuracy for conditions more prevalent in South Asian genetic backgrounds.
• Infrastructure disparity: Even basic genetic testing is unavailable in most district hospitals and primary health centers. The gap between urban and rural pediatric care remains wide.
• Awareness: Many pediatricians, particularly those practicing outside metro cities, are not yet equipped with the knowledge or resources to order, interpret, or act on genomic test results.

These are not insurmountable obstacles, but they require deliberate policy focus, investment in medical education, and public health advocacy.

The Path Forward: What India Must Do

The future of personalized pediatric medicine in India depends on a convergence of policy action, research investment, clinical education, and technology adoption. Several priorities stand out:

A national pediatric genomics programme, modelled along the lines of genomic medicine initiatives in the United Kingdom and Australia, could significantly advance the field in India. Such a programme would aim to sequence the genomes of children with rare diseases, childhood cancers, and complex multisystem disorders, building an India-specific database that improves diagnostic accuracy over time.

Medical education reforms are also essential. Pharmacogenomics and precision medicine must be introduced into undergraduate and postgraduate medical curricula, ensuring that the next generation of Indian pediatricians is equipped to integrate these tools into everyday clinical care. The National Medical Commission has an important role to play in this regard.

Platforms like Medicircle, which serve as bridges between medical experts and the wider public, can contribute meaningfully by raising awareness among parents, caregivers, and the broader healthcare community about developments in personalized pediatric medicine, making credible, expert-led information accessible to families across India.

Conclusion

Personalized medicine for children represents a profound shift in how healthcare thinks about the young patient. It recognises that each child is biologically unique, that their genetic profile, developmental stage, and environmental context all shape how they become ill and how they respond to treatment. From pharmacogenomics to genomic diagnosis of rare diseases, from precision nutrition to AI-assisted diagnostics, the field is advancing rapidly.

For India, the journey has begun. Tertiary hospitals are building genomic capabilities. Government policy is beginning to acknowledge the importance of rare disease care. Research institutions are generating India-relevant evidence. The task ahead is to ensure that these advances do not remain confined to elite urban healthcare but reach the millions of children across the country who deserve accurate diagnoses, effective treatments, and the best possible start to life.

The next frontier in pediatric care is not distant. It is being built today, one genetic insight at a time.

Frequently Asked Questions

Q1: What is personalized medicine in pediatrics?

Personalized medicine in pediatrics means tailoring a child's treatment plan based on their unique genetic profile, developmental stage, and environmental factors rather than using a standard, one-size-fits-all approach. It uses tools like genomic sequencing and pharmacogenomics to make clinical decisions more precise and effective.

Q2: Is personalized medicine available for children in India?

Leading Indian hospitals and research institutions have begun adopting genomic testing and pharmacogenomics for select pediatric conditions, particularly rare genetic diseases and childhood cancers. However, access remains largely limited to urban tertiary care centres, and wider availability is still a work in progress.

Q3: What is pharmacogenomics and how does it help children?

Pharmacogenomics is the science of understanding how a child's genetic variants influence their response to specific medications, including how quickly they metabolise a drug and whether they are likely to experience adverse effects. It helps doctors choose the right drug at the right dose from the outset, reducing trial and error and improving safety.

Q4: What are the challenges of implementing personalized medicine for children in India?

Key challenges include the high cost of genetic testing, a shortage of trained clinical geneticists, limited genomic infrastructure outside metro cities, the absence of large India-specific pediatric genomic databases, and low awareness among both clinicians and families about what personalized medicine involves.

Q5: Can personalized medicine help children with rare diseases?

Yes, significantly. Whole-exome and whole-genome sequencing have demonstrated diagnostic yields of 40 to 50 percent in carefully selected pediatric populations with rare or undiagnosed conditions. Early and accurate genomic diagnosis enables timely, targeted interventions and reduces the prolonged diagnostic journey that many families currently experience.

Resources

1. Indian Council of Medical Research (ICMR): Guidelines and research publications on child health, genomics, and rare diseases in India.
2. World Health Organization (WHO) India Country Office: Reports on child health priorities, essential medicines for children, and precision health initiatives in low- and middle-income countries.
3. Ministry of Health and Family Welfare, Government of India: National Policy for Rare Diseases and Ayushman Bharat scheme updates relevant to pediatric care.
4. PubMed, National Center for Biotechnology Information (NCBI): Peer-reviewed research on pharmacogenomics, pediatric precision medicine, and genomic diagnostics in children.
5. Indian Academy of Pediatrics (IAP): Clinical guidance, white papers, and position statements on evolving pediatric health priorities in India.

Interlinking Keywords:

pediatric care in India, rare diseases in children, pharmacogenomics for children, childhood cancer treatment India, precision medicine India, genomic testing children, Ayushman Bharat child health, personalized treatment pediatrics

Last Medically Reviewed By:

Editorial Medical Team, Medicircle on 2 September 2026

Medical Disclaimer:

The information provided in this article is intended for general awareness and educational purposes only. It does not constitute medical advice, diagnosis, or a treatment recommendation. Parents and caregivers should always consult a qualified and registered medical professional, such as a licensed pediatrician or clinical geneticist, before making any healthcare decisions for their child. Medicircle does not endorse any specific treatment, diagnostic test, institution, or healthcare provider mentioned in this article.